What are the Forrest classification grades for bleeding peptic ulcers and the recommended endoscopic and medical management for each grade?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Forrest Classification for Bleeding Peptic Ulcers

The Forrest classification stratifies bleeding peptic ulcers into high-risk lesions requiring endoscopic hemostasis (Forrest Ia, Ib, IIa) versus low-risk lesions managed with PPI therapy alone (Forrest IIc, III), with Forrest IIb (adherent clot) representing a controversial intermediate category.

Classification System

The Forrest classification divides bleeding ulcers into six categories based on endoscopic appearance 1, 2:

High-Risk Stigmata (Require Endoscopic Hemostasis)

  • Forrest Ia: Spurting/arterial bleeding - active pulsatile hemorrhage
  • Forrest Ib: Oozing bleeding - active non-pulsatile hemorrhage
  • Forrest IIa: Non-bleeding visible vessel - raised pigmented protuberance in ulcer base

Intermediate Risk

  • Forrest IIb: Adherent clot - overlying clot adherent to ulcer base

Low-Risk Stigmata (No Endoscopic Hemostasis Needed)

  • Forrest IIc: Flat pigmented spot - non-protuberant pigmented dot
  • Forrest III: Clean ulcer base - no stigmata of hemorrhage

Important caveat: Forrest Ib (oozing) actually carries lower rebleeding risk than Forrest IIa (visible vessel) or IIb (adherent clot), despite being classified as "active" bleeding 2.

Management Algorithm by Forrest Grade

Forrest Ia and Ib (Active Bleeding)

Endoscopic therapy is mandatory 1:

  • Dual therapy required: Epinephrine injection (1:10,000) PLUS a second modality 1

    • Epinephrine alone provides suboptimal efficacy and should never be used as monotherapy
    • Second modality options: thermocoagulation (heater probe, bipolar, APC), clips, or sclerosant injection
    • No single thermal method is superior to another 1
  • Pharmacologic management:

    • High-dose IV PPI: 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours 1, 2
    • Continue twice-daily oral PPI through day 14, then once daily 1
    • PPI for 6-8 weeks total to allow mucosal healing 2
  • Hospitalization: Minimum 72 hours after endoscopic hemostasis 1

Forrest IIa (Non-Bleeding Visible Vessel)

Endoscopic hemostasis is indicated - these lesions carry high rebleeding risk 1:

  • Same dual therapy approach as Forrest Ia/Ib
  • Same high-dose PPI regimen
  • Same hospitalization duration

Forrest IIb (Adherent Clot)

This grade is controversial 1, 2:

  • Attempt targeted irrigation to dislodge the clot 1
  • If clot dislodges: Treat any underlying Forrest Ia, Ib, or IIa lesion with endoscopic hemostasis
  • If clot remains adherent: Two acceptable approaches:
    • Intensive PPI therapy alone may be sufficient 1
    • Endoscopic therapy may be considered 1

The WSES guidelines advocate a cautious, non-aggressive approach to clot dislodgment rather than mechanical removal 2. Individual endoscopist judgment is appropriate here, as evidence remains insufficient to mandate one approach.

PPI therapy: High-dose IV infusion for 72 hours regardless of whether endoscopic therapy is performed 1

Forrest IIc and III (Low-Risk Lesions)

No endoscopic hemostasis indicated - rebleeding risk is minimal 1:

  • Standard oral PPI once daily 1
  • Early discharge is appropriate - patients can be fed within 24 hours and discharged home 1
  • No hospitalization required for observation in most cases

Exception: Patients with Forrest IIc lesions AND Rockall score ≥6 have significantly higher rebleeding risk (18.6% vs 2.9%) and warrant closer monitoring 3.

Additional Management Principles

Timing of Endoscopy

  • Perform early endoscopy within 24 hours of presentation 1
  • Very early endoscopy (<12 hours) for hemodynamically unstable patients despite resuscitation 4

Pre-Endoscopy Management

  • Erythromycin 250 mg IV given 30-120 minutes before endoscopy improves visualization and reduces need for second-look endoscopy 2, 4
  • Start high-dose PPI before endoscopy, but do not delay endoscopy for PPI administration 1, 4

Rebleeding Management

  • First rebleeding: Repeat endoscopy with second attempt at hemostasis 1
  • Second endoscopic failure: Consider transcatheter angiographic embolization or surgery 1, 2
  • Routine second-look endoscopy is NOT recommended 1

H. pylori Management

  • Test all patients for H. pylori in acute setting 1
  • Initiate eradication therapy if positive
  • Retest if initially negative (acute setting tests can be falsely negative)
  • Confirm successful eradication 1

Antiplatelet Management

For patients on aspirin for secondary cardiovascular prophylaxis:

  • Low-risk lesions (IIc, III): Resume aspirin immediately after index endoscopy 4
  • High-risk lesions (Ia, Ib, IIa, IIb): Resume aspirin by day 3 after adequate hemostasis established 4

Critical pitfall: Do not use H2-receptor antagonists, somatostatin, or octreotide - these provide no benefit in acute ulcer bleeding 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.